Φορτώνει......
Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
BACKGROUND: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non–small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline “window-of-opportunity” study. METHODS: Patients received 25 mg of temsirolimus administered intravenously...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Thorac Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2012
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5740874/ https://ncbi.nlm.nih.gov/pubmed/22722792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31824de0d6 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|